Please assess the completion status of the following clinical trial:

Trial Title: Modafinil in Opioid Induced Sedation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Epworth Sleepiness Scale \> 10~* Etiology of sleepiness is attributed only to opioids~* Patient must have been taking an opioid for more than 2 weeks or have been on a non-escalating dose of opioids for at least 1 week~* Patient must be able to give written informed consent~* Age \>18 years~Exclusion Criteria:~* Hypersensitivity to modafinil~* Mini-Mental Status Exam (MMSE) \< 25/30~* Renal impairment (calculated creatinine clearance \< 40)~* Hepatic dysfunction (total bilirubin \> 1.8, AST \> 75IU/l, ALT \> 100IU/l, prothrombin time \> 40%~* Known history of cardiovascular disease (i.e., left ventricular hypertrophy, ischemic ECG changes, chest pain, arrhythmia, mitral valve prolapse, recent myocardial infarction, unstable angina, uncontrolled hypertension)~* Woman who are pregnant, breast-feeding or on hormonal contraception~* Patients taking tricyclic antidepressants, CNS stimulants, hormonal contraceptives or drugs that are inhibitors or inducers of CYP 3A4

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).